Unnatural Products Partners with Novartis in $1.7 Billion Macrocyclic Peptide Deal for Cardiovascular Therapeutics
Key Insights
Unnatural Products (search) signed a licensing agreement with Novartis to develop macrocyclic peptide-based therapies for cardiovascular disease (search), with potential payments up to $1.7 billion.
The California biotech will receive up to $100 million in upfront and pre-IND milestone payments, plus tiered royalties ranging from mid-single to low double-digits on net sales.
Novartis will lead clinical development, manufacturing, and global commercialization of resulting drugs, leveraging UNP's AI-enhanced macrocycle platform.
Unnatural Products (search), a California-based biotech company, announced a research collaboration and licensing agreement with Novartis to develop macrocyclic peptide therapeutics for cardiovascular disease (search) applications. The deal structure includes up to $100 million in upfront and pre-IND milestone payments, with total potential payments reaching $1.7 billion through development, regulatory, and commercial milestones.
Under the agreement terms, Unnatural Products (search) will also receive tiered royalties ranging from mid-single up to low double-digits on annual net sales. Novartis will assume responsibility for IND-enabling studies and all subsequent clinical development, manufacturing, and global commercialization of products emerging from the collaboration.
Platform Technology and Therapeutic Approach
The collaboration combines Unnatural Products (search)' AI-enhanced macrocycle platform with Novartis' global development and commercialization capabilities. Macrocyclic peptides (search) represent a therapeutic class that merges the selectivity and potency of biologics with the flexibility and drug-like properties of small molecules, enabling access to previously undruggable targets (search).
Unnatural Products (search)' integrated discovery engine combines AI-guided molecular design, massively parallel synthesis, and direct-to-biology screening to rapidly generate highly potent and selective macrocycles suited for both oral and injectable modalities. The company's platform addresses the complexities of medicinal chemistry in the macrocycle space through a combination of parallel experimentation and machine learning.
Leadership Perspectives
"This collaboration validates the strength of our program and highlights the ability of UNP's platform to deliver differentiated macrocyclic therapeutics for high-value biological targets for chronic diseases with high unmet need," said Cameron Pye, Ph.D., CEO and Co-Founder of Unnatural Products (search). "Novartis has built a highly respected engine in cardiovascular innovation, and we are excited to collaborate with them to unlock the full therapeutic potential of this asset."
Muneto Mogi, Global Head of Global Discovery Chemistry, Biomedical Research at Novartis, emphasized the potential of macrocyclic chemistry: "Advances in macrocyclic chemistry are opening entirely new avenues in drug discovery, allowing us to engage targets at a dose and with a pharmacological versatility not possible with many other approaches. We believe this collaboration positions both organizations to accelerate the development of new therapies with strong scientific and clinical potential."
Strategic Implications
The partnership represents a significant validation of Unnatural Products (search)' macrocyclic peptide platform technology. Founded by macrocycle pioneers whose academic work uncovered how Nature's macrocycles work, the company is developing a portfolio of therapeutic macrocycles against high-value and traditionally difficult-to-drug targets.
Macrocyclic peptides (search) are shaped into a ring-like structure, which gives them advantages over traditional small-molecule drugs and larger biologics. This structural characteristic allows for enhanced stability and specificity while maintaining favorable pharmacological properties for drug development.
The companies did not disclose the exact nature of the cardiovascular program being developed under this collaboration, but the substantial financial commitment suggests significant therapeutic potential in addressing unmet medical needs in cardiovascular disease (search).